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Idiopathic pulmonary ﬁbrosis (IPF) is a severe, rapidly progressive diﬀuse lung disease. Several pathogenetic mechanisms
have been hypothesized on the basis of the ﬁbrotic lung damage occurring in this disease, and a potential proﬁbrotic role of
activated alveolar macrophages and their mediators in the pathogenesis of IPF was recently documented. This paper focuses on
recent literature on potential biomarkers of IPF derived from activated alveolar macrophages. Biomarker discovery and clinical
application are a recent topic of interest in the ﬁeld of interstitial lung diseases (ILDs). Cytokines, CC-chemokines, and other
macrophage-produced mediators are the most promising prognostic biomarkers. Many molecules have been proposed in the
literature as potential biomarker of IPF; however, a rigorous validation is needed to conﬁrm their clinical utility.
1.Introduction
Interstitial lung diseases (ILDs) are a heterogeneous group of
rare diseases with diﬀerent etiopathogenesis and clinical evo-
lution [1]. They include idiopathic pulmonary ﬁbrosis (IPF),
a chronic progressive lung disease of unknown etiology, and
a prognosis of 3–5 years [2]. The diﬃculty of early diagnosis
of IPF, of diﬀerentiating IPF/UIP from various idiopathic
interstitial pneumonias and the impossibility of predicting
patient outcome (as there exist diﬀerent phenotypes of IPF)
have prompted research into biomarkers [3]. The need for
diagnostic and prognostic biomarkers is a topical subject
for all chest physicians involved in the management of
ILD patients and particularly IPF. Useful biomarkers have
to be readily detectable in biological ﬂuids by noninvasive
and reproducible procedures and must be demonstrated
suﬃciently sensitive and speciﬁc by appropriate statistical
analysis [4]. Identiﬁcation of new biomarkers of ILD is
a growing ﬁeld of research, favoured by the development
of new technologies such as genomics and proteomics
that can reveal genetic mutations, polymorphisms, proteins,
peptides, and other molecules with a potential role as
biological indicators [5, 6]. Modern clinical management of
patients with IPF envisages biomarkers with diagnostic and
prognostic value, though not a single biomarker, has yet
provided suﬃcient evidence to be implemented in routine
patient management [3].
Several pathogenetic mechanisms have been postulated
on the basis of ﬁbrotic lung damage occurring in patients
with IPF. The inﬂammatory theory has been partially
replaced by the concept of aberrant wound healing due to
interactions between epithelial cells and ﬁbroblasts, deter-
mining uncontrolled chronic ﬁbroproliferation [7]. More
recently, studies on cytokine and chemokine expression in
serum and BAL have suggested a potential proﬁbrotic role
of activated alveolar macrophages and their mediators in
the pathogenesis of IPF [8, 9]. For example, IL13 and
some CC-chemokines are directly implicated as mediators
of these macrophages [10]. Alveolar macrophages are a
heterogeneous population of cells derived from monocytes,
with multiple immunological functions. They defend the
lungs by phagocytic activity, taking part in aspeciﬁc mech-
anisms of defence as well as speciﬁc immune responses
via secretory activity [11, 12]. Alveolar macrophages are
the most abundant cell population in bronchoalveolar
lavage (BAL). Activated alveolar macrophages can release
cytokines, growth factors, extracellular matrix proteins, and
tissue inhibitors of metalloproteases, contributing to alveolar2 Pulmonary Medicine
Table 1: The main features of macrophage-derived biomarkers of idiopathic pulmonary ﬁbrosis.
CCL18 IL8 CCL2 S100A9 MIF
Cellular production
Monocytes/
Macrophages,
Dentritic cells
Macrophages,
Epithelial cells
Monocytes/
Macrophages,
Fibroblasts,
Epithelial cells,
Endothelial cells
Monocytes/
Macrophages,
Neutrophils
Macrophages,
Tc e l l s
Biological ﬂuids Serum, Lung
tissue, BAL Serum, BAL Serum, BAL BAL, Lung tissue BAL, Lung tissue
Concentrations in
IPF versus controls Increased Increased Increased Increased Increased
Correlation studies
with clinical
parameters
YES YES YES YES None
Studies on other
ILDs (speciﬁcity)
Sarcoidosis, NSIP,
Systemic sclerosis,
Hypersensitivity
pneumonitis, Vasculitis,
Smoking-related ILD
Sarcoidosis,
Systemic
sclerosis, BOOP,
Vasculitis,
Hypersensitivity,
pneumonitis
Sarcoidosis,
Systemic sclerosis
Hypersensitivity,
pneumonitis, BOOP,
AIP, Silicosis
Sarcoidosis,
Systemic sclerosis
Sarcoidosis,
Wegener’s
granulomatosis,
Systemic sclerosis,
Hypersensitivity
pneumonitis
Studies on other
lung diseases
Malignancies,
TB, Asthma
Bronchiolitis,
Cancer,
Asthma COPD,
Cystic ﬁbrosis,
ARDS
Malignancies,
Asthma, TB
Malignancies,
Pneumonia
Lung cancer,
Pneumoniae,
Asthma, ARDS
injury and aberrant lung repair occurring in IPF [13–16].
Study of the macrophage model of activation suggests the
existence of classical and alternative modes of activation.
The classical mode is mediated by type 1 proinﬂammatory
cytokines, while type 2 cytokines induce the alternative
mode, facilitating release of proﬁbrotic mediators and pro-
moting ﬁbrogenetic processes with aberrant production and
deposition of collagen in the lungs [15, 16]. Studies on BAL
ﬂuid show that alveolar macrophages have a crucial role in
the pathogenesis of ILD in general, for example, in sarcoido-
sis, where they mediate abnormal lymphocyte proliferation
and granuloma formation by inducing antigen presentation
[17, 18]. In IPF, alveolar macrophages play a proﬁbrotic
role through release of ﬁbronectin, insulin growth factor,
PDGF, and other mediators [19, 20]. Alternative activated
macrophages(M2phenotype)arecrucialinthepathogenesis
of IPF enhancing ﬁbrogenesis of ﬁbroblasts by providing
proﬁbrogenic factors [21], favouring cell growth, collagen
formation, and tissue repair [22]. Prasse et al. demonstrated
that alternative activated macrophages trigger a vicious circle
between alveolar macrophages and ﬁbroblasts by releasing
IL10,IL1receptorantagonist,andCCL18 (alsonamedPARC
or MIP-4), which promote collagen deposition and ﬁbrotic
progression of IPF [9]. Moreover, very recently Pechkovsky
et al. conﬁrmed the crucial role for M2 macrophages in
the pathogenesis of IPF reporting elevated spontaneous
production of the chemokines CCL17, CCL18, and CCL22
and increased expression of CD206 by alveolar macrophages
from patients with lung ﬁbrosis. They also obeserved that
IL-4 was the most powerful inducer of M2-phenotype in
alveolar and monocytes from IPF patients [15].
Analysis of recent literature on biomarkers derived from
activated alveolar macrophages in IPF is the main topic of
this paper.
2. Macrophage-Derived Biomarkers of IPF
In the last few years, molecules of diﬀerent origin have
been proposed as potential biomarkers of IPF. Fibrocytes,
neutrophils, and alveolar epithelial cells are sources of medi-
ators involved in the pathogenesis of IPF and proposed as
candidate biomarkers, for example, KL6, surfactant proteins
A and D, or circulating ﬁbrocytes [23–26]. Although many
molecules expressed by alveolar macrophages (cytokines
such as IL13 and TGF-beta, CC chemokines, and many
enzymes, receptors, and growth factors, such as PDGF) have
been studied in diﬀerent biological ﬂuids of IPF patients
in order to evaluate their contribution to pathogenesis,
only a limited number have been investigated for clinical
biomarker potential by seeking correlations between their
concentrations and parameters of clinical prognostic [3, 15,
21, 27–32].
CC Chemokine Ligand 18 (CCL18). has been widely studied
in BAL, serum, and tissue of IPF patients, proving a very
promising biomarker derived from alternatively activated
alveolar macrophages (Th2 cytokines and IL10 induce its
biosynthesis) and highly expressed in the lungs [15, 33–
35]( Table 1). In 2006, a group of German researchers
demonstrated that normal human alveolar macrophages
express CCL18 spontaneously, but its production is muchPulmonary Medicine 3
higher (more than 100-fold) in IPF patients than controls
[15]. They also demonstrated that contact and exposure of
ﬁbroblasts to native collagen induces spontaneous release of
CCL18 by M2 macrophages, which also upregulate collagen
production by lung ﬁbroblasts [15]. CCL18 has therefore
been recognised as a mediator of positive feedback between
alveolar macrophages and ﬁbroblasts, promoting collagen
deposition in IPF. The eﬀectiveness of CCL18 as a biomarker
of IPF activity was later documented by measuring its con-
centrations in serum, BAL, and BAL cell supernatants from a
group of IPF patients [33]. Concentrations in serum strictly
reﬂected the time trend of certain functional parameters
(such as TLC) in these patients. An inverse correlation was
also found between spontaneous release of BAL CCL18 and
TLCor DLCO;aswell,a direct correlation wasdemonstrated
betweenBALCCL18concentrationsandBALneutrophiland
eosinophil counts [33]. The prognostic value of CCL18 was
recently reported in a prospective study that documented
signiﬁcantly higher mortality in IPF patients with serum
CCL18 concentrations above 150ng/ml [35]. High levels of
CCL18 in serum were associated with high risk of disease
progression.CCL18isthereforeanimportantM2biomarker;
its concentrations are elevated not only in serum of IPF
patients but also in other ILDs with active ﬁbrosis, and to a
lesser extent in serum of patients with bronchial asthma and
rheumatoid arthritis [33, 34]. Extension of CCL18 studies
to a larger population will enable deﬁnition of its potential
use in clinical practice for the management of IPF patients.
This chemokine could be particularly useful, especially as a
prognostic indicator of patient survival.
Alveolar macrophages can release other CC chemokines
that could be implicated in ﬁbrogenesis, including CC
chemokine ligand 2 (CCL2 or monocyte chemoattractant
protein-1, MCP-1) that together with CCL3 and CCL4,
provedhigherinBALofIPFpatientsthancontrols[8,32,36–
38].CCL2levelsinBALwereinverselycorrelatedwithDLCO
v a l u e sa n da rt e r i a lo x y g e nt e n s i o ni nI P F[ 32, 36]. Shinoda et
al. suggested that elevated concentrations of CCL2, CCL17,
and CCL22 in BAL ﬂuid may be predictive of poor outcome
in patients with IPF, being associated with poor survival rate
[32]. Concentrations of CCL-2 can also be increased not
only in BAL but also in serum and of IPF patients (Table 1);
indeed, Suga et al. suggested that the clinical evolution
of the disease is correlated with serum CCL2 chemokine
concentrations [37]. The potential application of CCL2 as
a clinical biomarker of IPF seems to be limited by its low
speciﬁcity; its serum concentrations are higher in connective
tissue lung diseases than in IPF, and common nonrespiratory
diseases such as atherosclerosis may raise levels, acting as a
confounding factor [38, 39].
IL-8. (also known as neutrophil chemotactic factor) is a
major mediator of inﬂammatory response. Produced by
alveolar macrophages, epithelial cells, and other cell types,
it functions as a chemoattractant for neutrophilic granu-
locytes, macrophages, endothelial cells, and mast cells and
as a potent angiogenic factor [40]. Concentrations of IL-
8 in serum can be inﬂuenced by several factors, including
infectious diseases (Table 1)[ 41]. More than 10 years ago,
Ziegenhagen et al. reported higher concentrations of this
CXC chemokine in serum and BAL of patients with IPF
than normal controls [42]. They also reported positive
correlations between serum and BAL concentrations of IL-8
and neutrophil percentages in BAL [42]. Serum levels of this
chemokine were inversely correlated with lung function data
(DLCO, VC, TLC) and oxygen pressure measured by blood
gas analysis in this population of IPF patients. The authors
suggested that IL-8 may be a useful clinical marker in the
followup of IPF patients [42]. After this study, other research
conﬁrmedtheveryhighlevelsofIL8inserumofIPFpatients,
as well as inverse correlations with functional parameters
(mainly FVC) [43, 44]. A Japanese study indicated that
high serum levels of IL-8 can be observed in patients with
active disease, while stable IPF patients had low serum
concentrations of IL-8 [44]. The correlation between IL8
concentrations and mortality rate has never been tested. IL-
8 is a potential biomarker of IPF with limited speciﬁcity
that could possibly be included in a cluster of biomarkers to
deﬁne their eﬀective prognostic power in a larger group of
patients.
The complex pathogenetic mechanisms and lack of
diagnostic and prognostic biomarkers of IPF have driven
proteomic research in the last few years. Several proteomic
s t u d i e sh a v eb e e nd o n e ,a n dap r o t e o m i ca p p r o a c hh a sb e e n
used to analyse protein composition of BAL from diﬀerent
ILD, including IPF, identifying proteins of interest [6, 45–
49]. Calgranulin B and MIF, produced by activated alveolar
macrophages were among those expressed diﬀerently in IPF
patients than controls [49–51]( Table 1).
Calgranulin B (S100A9 or MRP14). Is a S100 protein pro-
duced by monocyte-macrophages, neutrophils, and other
cells mainly in response to chronic inﬂammatory processes
[52]. S100A9 is involved in the regulation of a number
of cell processes such as cell cycle progression and dif-
ferentiation [53]. Recent data suggests that this protein
has a crucial role in inﬂammation, cancer, and ﬁbrotic
lung remodeling [54]. It interacts with extracellular matrix
proteins, stimulates ﬁbroblast proliferation, and regulates
transendothelial migration of leukocytes and adhesion of
neutrophils to ﬁbrinogen via beta 2 integrin Mac-1 [55,
56]. Its interactions with RAGE receptors (other proﬁbrotic
agents implicated in the regulation of extracellular matrix
degradation in IPF) facilitate neutrophil migration from
endothelium to interstitium, adhesion of neutrophils to
ﬁbronectin, and ﬁbrotic lung remodeling [57]. Calgranulin
B is overexpressed in breast, lung and gastrointestinal cancer,
autoimmune inﬂammatory diseases, and COPD and cystic
ﬁbrosis [58–60]. In 2002, calgranulin B was identiﬁed for
the ﬁrst time in BAL of IPF and sarcoidosis patients by a
proteomic approach using gel matching and MALDI-TOF
mass ﬁngerprinting [49]. Percentage volumes of calgranulin
B proved signiﬁcantly higher in BAL of IPF patients than
sarcoidosis patients or patients with pulmonary ﬁbrosis
associated with systemic sclerosis or controls (Figure 1)
[45]. Quantitative analysis (ELISA) conﬁrmed the very high4 Pulmonary Medicine
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Figure 1: Calgranulin B concentrations in BAL of sarcoidosis, idio-
pathic pulmonary ﬁbrosis patients and healthy controls (smokers
and nonsmokers). The box extends from the 25th percentile to the
75th percentile, with a line at the median (the 50th percentile).
Prism plots the whiskers to extend above and below the box to show
the highest and lowest values [61].
concentrations of this protein in BAL of IPF patients,
presumably due to the elevated number and massive acti-
vation of polymorphonuclear cells in this disease (indeed
calgranulin B concentrations in BAL showed a positive
correlation with neutrophil/eosinophil percentages in BAL)
[50]. The suitability of BAL calgranulin B as a disease
biomarker was suggested by an inverse correlation with
FVC and DLCO; the highest concentrations of calgranulin
B in BAL were observed in patients with the lowest FVC
and DLCO values [61]. Elevated BAL concentrations of
calgranulin B in IPF patients and a correlation with BAL
neutrophilcountswererecentlyalsoconﬁrmedbyKorthagen
et al. who additionally reported a moderate increase in
this protein, correlated with radiological stages, in BAL of
sarcoidosis patients [62]. Further study of calgranulin B
as a potential indicator of IPF severity and sarcoidosis is
warranted. The protein expression has to be analysed in
serum of IPF patients and in order to verify its speciﬁcity
also in serum and BAL samples of patients with diﬀerent
interstitial lung diseases.
Another interesting protein identiﬁed by a proteomic
approach in BAL of patients with IPF and diﬀerently
expressed in patients than controls is macrophage migration
inhibitory factor, MIF. MIF is a pleiotropic proinﬂammatory
cytokine produced by activated macrophages and potentially
involved in IPF pathogenesis for its numerous functions
including regulation of cell redox status, inhibition of apop-
tosis, induction of matrix metalloproteinases, and regulation
of Th1/Th2 immune responses [51]. Its concentrations in
BALofIPFpatientsareveryhighanddirectlycorrelatedwith
BAL neutrophil percentages. Immunohistochemical analysis
of MIF revealed enhanced expression from actively ﬁbrosing
areas, such as ﬁbroblast foci and lung remodeling zones
[51]. The role of MIF as a disease biomarker needs to be
investigated. Potential correlations with clinical parameters
(including mortality rate) in IPF patients and the expression
of MIF in other interstitial lung diseases have to be furtherly
analysed.
3. Conclusion
The recent literature on IPF indicates great interest in
developing diagnostic and prognostic biomarkers and in
deﬁning the potential role of activated macrophages in the
pathogenesis of IPF. Potential IPF biomarkers derived from
activated alveolar macrophages, currently being studied,
include CCL18, CCL2, IL-8, and calgranulin B.
The discovery and development of biomarkers has to
be conducted in a rigorous manner; studies on potential
biomarkers have to be performed on a large scale, and
appropriate statistical analysis is necessary to validate a
molecule as a real biological indicator [4, 63]. In the last few
years, only a limited number of molecules analysed in ILD
have made the transition from candidate to true biomarker
status because of the diﬃculties associated with validating
biomarkers. Among those analysed in this paper, CCL18
seems the most promising macrophage-derived biomarker
of IPF, especially because it is clearly correlated with patient
mortality [35]. However, before serum assay of CCL18 can
be used in the clinical management of IPF patients, further
analysis on a larger populations is required.
Macrophage-derived biomarkers of IPF are proteins
overexpressed in serum, BAL samples, or lung tissue of
patients with IPF compared with controls. An alternative
approach to identify potential bioindicators of IPF has been
suggested by Ren et al. who reported evidence of impaired
transcription in IPF macrophages. The authors concluded
thatthedetectionofadecreaseinaspeciﬁcproteinproduced
by macrophages would be an alternative method to identify
potential bioindicators of this severe interstitial lung disease
[64].
Sophisticated methods applied to diﬀerent biological
ﬂuids are revealing interesting new groups of molecules
that could provide future biomarkers of IPF, useful for ﬁne
phenotyping of patients and for clinical management of the
disease.
Abbreviations
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